​

TScan Therapeutics (TCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TCRX Stock Forecast

TScan Therapeutics (TCRX) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 380.00% increase from the last price of $2.50.

$2 $4 $6 $8 $10 $12 High: $12 Avg: $12 Low: $12 Last Closed Price: $2.5

TCRX Stock Rating

TScan Therapeutics stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 2 Strong Sell Sell Hold Buy Strong Buy

TCRX Forecast vs Benchmarks

TypeNameUpside
StockTScan Therapeutics380.00%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$2.50$2.50$2.50
Upside/Downside--380.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2544---8
Dec, 2444---8
Nov, 2446---10
Oct, 2446---10
Sep, 2446---10
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 16, 2024Justin ZelinBTIG$12.00$8.9334.38%380.00%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2024WedbushBuyBuyhold
Jun 04, 2024NeedhamUnderperformUnderperformhold
May 16, 2024BTIGBuyinitialise
May 13, 2024WedbushBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.17$-2.74$-1.36-----
Avg Forecast$-6.39$-2.76$-1.54$-1.27$-1.28$-1.33$-1.12$-0.92
High Forecast$-14.88$-5.33$-1.65$-1.31$-1.45$-1.57$-1.60$-1.90
Low Forecast$-0.26$-0.55$-1.32$-1.23$-1.09$-1.04$-0.81$-0.04
Surprise %-34.74%-0.72%-11.69%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.14M$13.54M$21.05M-----
Avg Forecast$11.32M$13.89M$16.86M$3.61M$6.98M$11.95M$26.31M$69.32M
High Forecast$2.96M$5.34M$15.65M$2.92M$1.85M$3.16M$6.96M$18.33M
Low Forecast$22.88M$23.84M$18.54M$4.69M$12.73M$21.79M$47.97M$126.38M
Surprise %-10.40%-2.58%24.84%-----

Net Income Forecast

$-1B $-800M $-600M $-400M $-200M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.63M$-65.81M$-89.22M-----
Avg Forecast$-419.31M$-181.06M$-89.22M$-83.10M$-83.23M$-85.45M$-79.05M$-60.35M
High Forecast$-976.21M$-349.53M$-108.21M$-85.71M$-95.02M$-103.00M$-104.96M$-124.93M
Low Forecast$-16.97M$-36.15M$-86.28M$-80.49M$-71.45M$-67.90M$-53.14M$-2.64M
Surprise %-88.40%-63.65%------

TCRX Forecast FAQ

Is TScan Therapeutics stock a buy?

TScan Therapeutics stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TScan Therapeutics is a favorable investment for most analysts.

What is TScan Therapeutics's price target?

TScan Therapeutics's price target, set by 2 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 380.00% change from the previous close price of $2.5.

How does TScan Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

TScan Therapeutics stock forecast shows a 380.00% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for TScan Therapeutics over the past three months?

  • January 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is TScan Therapeutics’s EPS forecast?

TScan Therapeutics's average annual EPS forecast for its fiscal year ending in December is -1.27 for 2024, a -6.62% decrease from the reported $-1.36 in 2023. The prediction for 2025 is $-1.28, $-1.33 for 2026, $-1.12 for 2027, and $-0.92 for 2028.

What is TScan Therapeutics’s revenue forecast?

TScan Therapeutics's average annual revenue forecast for its fiscal year ending in December is $3.61M for 2024, a -82.86% decrease from the reported $21.05M in 2023. The forecast for 2025 is $6.98M, $11.95M for 2026, $26.31M for 2027, and $69.32M for 2028.

What is TScan Therapeutics’s net income forecast?

For its fiscal year ending in December, TScan Therapeutics's average annual net income forecast is $-83.103M for 2024, reflecting a -6.85% decrease from the reported $-89.218M in 2023. The projection for 2025 is $-83.231M, $-85.45M for 2026, $-79.048M for 2027, and $-60.352M for 2028.